By Fineline Cube 
US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that its HIV pre-exposure prophylaxis (PrEP) drug, lenacapavir, has been approved by the Hainan Boao Lecheng International Medical Tourism Pilot Zone. The approval is for adults and adolescents weighing ≥35 kg at risk of HIV-1 infection to reduce the risk of sexually acquired HIV-1.
Drug Mechanism
Lenacapavir works by providing multistage inhibition of the HIV lifecycle. This mechanism of action contributes to its significant preventive efficacy.
Clinical Trial Results
The approval is supported by results from the Phase III PURPOSE trials, which demonstrated the drug’s effectiveness in preventing HIV-1 infection.